Business Context and Reporting Period
Company: AmerisourceBergen Corporation (Note: The input metadata references "Cencora," but the filing text identifies the registrant as AmerisourceBergen Corporation, the predecessor to Cencora).
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2006.
Business Overview: One of the world's largest pharmaceutical services companies, operating in the U.S., Canada, and the U.K. The company provides drug distribution and related services to healthcare providers and manufacturers. Operations are organized into two reportable segments: Pharmaceutical Distribution (wholesale, specialty, and packaging) and PharMerica (long-term care and workers' compensation services).
Key Financial Metrics
| Metric | Fiscal 2006 | Fiscal 2005 |
|---|---|---|
| Operating Revenue | $56.67 billion | $50.01 billion |
| Total Revenue (incl. bulk deliveries) | $61.20 billion | $54.58 billion |
| Gross Profit | $2.23 billion | $1.98 billion |
| Gross Margin | 3.94% | 3.96% |
| Operating Income | $748.7 million | $636.9 million |
| Operating Margin | 1.32% | 1.27% |
| Net Income | $467.7 million | $264.6 million |
| Diluted EPS | $2.25 | $1.24 |
| Cash and Equivalents | $1.26 billion | $966.6 million |
| Total Debt | $1.10 billion | $952.7 million |
| Operating Cash Flow | $807.3 million | $1.53 billion |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 13% to $56.7 billion, driven primarily by the Pharmaceutical Distribution segment (up 13%) and acquisitions in Canada. Bulk deliveries decreased slightly by 1%.
- Profitability: Net income surged 77% to $467.7 million. Operating income rose 18% to $748.7 million. This improvement was aided by a 78% reduction in net interest expense (due to debt refinancing) and gains from antitrust litigation settlements ($40.9 million).
- Segment Performance:
- Pharmaceutical Distribution: Operating income increased 21% to $644.2 million. The Specialty Group revenue grew 33% to $9.9 billion.
- PharMerica: Operating income declined 9% to $83.7 million due to increased bad debt expenses and costs related to the Medicare Part D transition.
- Acquisitions: The company expanded its Canadian footprint by acquiring Trent Drugs, Asenda, and Rep-Pharm. It also acquired Brecon (U.K. packaging), NMCR (oncology education), and others.
- Divestiture Plan: In October 2006, the company signed an agreement to combine its PharMerica Long-Term Care business with Kindred Healthcare to form a new independent company, expected to close in Q1 2007.
Guidance, Outlook, and Risks
- Revenue Guidance: Management expects operating revenue growth in fiscal 2007 to slow to a range of 7% to 9%, down from 13% in fiscal 2006. Specialty growth is expected to moderate to the mid-to-high teens.
- Cash Flow Outlook: Operating cash flow is expected to decline to a range of $525 million to $625 million in fiscal 2007 as the one-time working capital benefits from the fee-for-service transition are realized.
- Capital Allocation: The company announced a new $750 million share repurchase program in August 2006 and increased the quarterly dividend by 100% to $0.05 per share.
- Key Risks:
- Regulatory Changes: Ongoing impact of the Medicare Modernization Act (MMA) and Deficit Reduction Act (DRA) on reimbursement rates, particularly for the PharMerica segment.
- Competition: Intense competition from Cardinal Health and McKesson continues to pressure gross margins.
- Customer Concentration: The top ten customers represented 32% of operating revenue; the largest non-bulk customer represented 8%.
- Legal Contingencies: A pending lawsuit regarding a former executive resulted in a $13.9 million charge in fiscal 2006, with appeals ongoing.
Investor Verification Checklist
- Fee-for-Service Transition: Verify the sustainability of earnings as the company moves away from inventory appreciation profits toward service fees.
- PharMerica Spin-off: Monitor the progress and regulatory approval of the proposed combination with Kindred Healthcare, which will remove the Long-Term Care segment from the consolidated results.
- Reimbursement Pressures: Assess the impact of Medicaid and Medicare Part D reimbursement reductions on the PharMerica segment's margins.
- Antitrust Gains: Note that $40.9 million of gross profit in 2006 was derived from antitrust litigation settlements; evaluate future earnings without this non-recurring income.
- Debt Structure: Review the new multi-currency revolving credit facility and the reduction in the receivables securitization facility announced in November 2006.